An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Beatrice Society has announced the formation of its Board of Directors, appointing Gary Yeoman as Chairman. The board includes seasoned professionals Lorne Gertner and Krisztián Tóth. Yeoman, previously at Voxtur Analytics and Altus Group, aims to build on recent acquisitions in psychedelics and wellness. Gertner co-founded Cannasat Therapeutics and has notable ties to the cannabis industry, while Tóth specializes in corporate finance. The board's expertise is expected to strengthen Beatrice's position in the growing psychedelic therapy market.
Positive
Experienced board members bring valuable industry expertise.
Gary Yeoman's leadership expected to enhance strategic direction.
Recent acquisitions in the psychedelics and wellness space may improve market position.
Negative
Potential continuity concerns with new board formation.
Experience gaps may arise due to the transition.
Gary Yeoman to Serve as Chairman
TORONTO--(BUSINESS WIRE)--
Beatrice Society (“The Company” or “Beatrice”), a psychedelics and functional mushroom company focused on improving psychotherapy-driven patient outcomes and everyday quality of life, today announced the formation of its initial Board of Directors, including a new Chairman. The Board is currently comprised of three seasoned professionals, including:
Gary Yeoman, Chairman
Lorne Gertner, Director
Krisztián Tóth, Director
“We are pleased to welcome Gary Yeoman as Chairman, alongside highly qualified directors to Beatrice Society,” said John Baker, CEO of Beatrice Society. “Each director provides the company with valuable perspective and brings with them a wealth of experience. This fantastic slate of industry veterans will provide a solid foundation for building upon the successes of Beatrice’s latest acquisitions in the psychedelics and wellness space.”
Gary Yeoman Mr. Yeoman currently serves as Executive Chairman at Voxtur Analytics Inc. In 2013, he joined ILA (now Voxtur Analytics Corp.) as Chairman and was appointed CEO in 2017. Prior to this role, he founded and served as CEO of Altus Group (TSX:AIF), a leading provider of software, data solutions and independent advisory services to the global commercial real estate industry. Mr. Yeoman led Altus through an IPO in 2005 and a 7-year growth period during which the company realized a 333% increase in revenues from $75M to approximately $325M.
Lorne Gertner Lorne is a co-founder and board member of GoodCap Pharmaceuticals Inc. His prior experience in drug development includes co-founding Cannasat Therapeutics, which sold to Sunovion Pharmaceuticals Inc. (NASDAQ:SEPR) in 2016 for C$841 million. As a pioneer within Canada’s nascent cannabis industry, Mr. Gertner co-founded and served as Chairman of PharmaCan Capital Corporation, now Cronos Group Inc (TSX:CRON). He is also the co-founder of Tokyo Smoke, an industry-leading cannabis retailer purchased by Canopy Growth (TSX:WEED) in 2018.
Krisztián Tóth
Mr. Tóth currently serves as Partner at Fasken Martineau DuMoulin LLP. His practice focuses on mergers and acquisitions and corporate finance with an emphasis on cross-border transactions, proxy contests and other contested matters, public and private financings, securities regulations and corporate governance.
About Beatrice Society Beatrice Society Inc. exists to fuel the growing psychedelic therapy industry through public and professional education and therapies.
Beatrice’s consumer-oriented brand drives public awareness of psychedelic therapies through credible editorial content focused on answering common questions, and quality functional mushroom products that serve as an approachable introduction to the category.
Beatrice supports the mental health industry by equipping clinicians with patient-centred, evidence-based protocols for psychedelic-assisted psychotherapy treatment. Training existing clinicians in their proprietary TRIP™ protocol will help to alleviate the shortage of mental healthcare practitioners trained in psychedelic therapy, while their growing network of clinics allows for expedited expansion with consistency in both therapeutic process and post-integration analysis.
